Skip to main content

Table 1 Clinical characteristics of the study participants

From: Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families

 70 patients
Age at diagnosis, mean ± SD (range)46 ± 11 years (26–79)
Relatives with breast cancer, mean ± SD (range)4.1 ± 1.5 (1–9)
Histology
 - Ductal carcinoma84%
 - Medullary carcinoma or medullary-like4%
 - Other invasive carcinomas8%
 - Ductal in situ carcinoma4%
Grade
 - Grade 113%
 - Grade 255%
 - Grade 327%
 - Missing5%
Size, median (range)17 mm (2–115)
Ki67, median (range)20% (5–80)
Estrogen receptor +75%
Molecular classification
 - Luminal (A - B - ERBB2+)52% (15% - 34% - 16%)
 - ER− ERBB2+3%
 - Triple-negative13%
 - ERBB2 status missing19%
Positive lymph nodes34%
2nd breast cancer (of which contralateral)34% (81%)
Breast cancer lifetime residual risk, mean ± SD (range)15 ± 7% (2–30)26 NA
BRCA mutation carrier pre-test probability, median (range)13% (1–91)
  1. Breast cancer lifetime residual risk and BRCA mutation carrier pre-test probability as determined by BOADICEA [14]. Breast cancer lifetime residual risk cannot be assessed for patients having already presented bilateral breast cancer and ovarian cancer or > 80 years old
  2. SD standard deviation